Platelet reactivity and hemorrhage risk in neurointerventional procedures under dual antiplatelet therapy

被引：27

作者：

Nishi, Hidehisa ^{[1
]}

Nakahara, Ichiro ^{[2
]}

Matsumoto, Shoji ^{[1
,3
]}

Hashimoto, Tetsuya ^{[4
]}

Ohta, Tsuyoshi ^{[5
]}

Sadamasa, Nobutake ^{[1
]}

Ishibashi, Ryota ^{[1
]}

Gomi, Masanori ^{[1
]}

Saka, Makoto ^{[1
]}

Miyata, Haruka ^{[1
]}

Watanabe, Sadayoshi ^{[2
]}

Okata, Takuya ^{[1
]}

Sonoda, Kazutaka ^{[1
]}

Kouge, Junpei ^{[1
]}

Ishii, Akira ^{[1
]}

Nagata, Izumi ^{[1
]}

Kira, Jun-ichi ^{[3
]}

机构：

[1] Kokura Mem Hosp, Dept Neurosurg, Fukuoka, Japan

[2] Fujita Hlth Univ, Dept Neurosurg, Toyoake, Aichi, Japan

[3] Kyushu Univ, Grad Sch Med Sci, Neurol Inst, Dept Neurol, Fukuoka, Japan

[4] Natl Cerebral & Cardiovasc Ctr, Dept Cerebrovasc Med, Osaka, Japan

[5] Kochi Hlth Sci Ctr, Dept Neurosurg, Kochi, Japan

来源：

JOURNAL OF NEUROINTERVENTIONAL SURGERY | 2016年 / 8卷 / 09期

关键词：

Drug; Hemorrhage; Intervention; Pharmacology;

D O I：

10.1136/neurintsurg-2015-011844

中图分类号：

R445 [影像诊断学];

学科分类号：

100207 ;

摘要：

Background and purpose Hemorrhagic complications during neurointerventional procedures have various etiologies and can result in severe morbidity and mortality. This study investigated the possible association between low platelet reactivity measured by the VerifyNow assay and increased hemorrhagic complications during elective neurointervention under dual antiplatelet therapy. Methods From May 2010 to April 2013 we recorded baseline characteristics, P2Y12 reaction units (PRU), and aspirin reaction units using VerifyNow. The primary endpoint was post-procedural hemorrhagic complications. Results A total of 279 patients were enrolled and 31 major hemorrhagic complications (11.1%) were identified. From receiver-operating characteristic curve analysis, PRU values could discriminate between patients with and without major hemorrhagic complications (area under the curve 0.63). Aspirin reaction unit values had no association with the primary outcome. The optimal cut-off for the primary outcome (PRU <= 175) was used to identify the low platelet reactivity group. The incidence of hemorrhagic complications was 20.0% in this group and 8.9% in the non-low platelet reactivity group. Multivariate analysis identified low platelet reactivity as an independent predictor for hemorrhagic complications. Conclusions The risk of hemorrhagic complications during elective neurointervention including cerebral aneurysm coil embolization and carotid artery stenting under dual antiplatelet therapy is associated with the response to clopidogrel but not to aspirin. A PRU value of <= 175 discriminates between patients with and without hemorrhagic complications. Future prospective studies are required to validate whether a specific PRU value around 170-180 is predictive of hemorrhagic complications.

引用

页码：949 / 953

页数：5

共 23 条

[1] Bhatt D.L., Kapadia S.R., Bajzer C.T., Et al., Dual antiplatelet therapy with clopidogrel and aspirin after carotid artery stenting, J Invasive Cardiol, 13, pp. 767-771, (2001)
[2] Von Beckerath N., Pogatsa-Murray G., Wieczorek A., Et al., Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness, Thromb Haemost, 95, pp. 910-911, (2006)
[3] Jakubowski J.A., Payne C.D., Li Y.G., Et al., The use of the VerifyNow P2-12 point-of-care device to monitor platelet function across a range of P2-12 inhibition levels following prasugrel and clopidogrel administration, Thromb Haemost, 99, pp. 409-415, (2008)
[4] Varenhorst C., James S., Erlinge D., Et al., Assessment of P2-(12) inhibition with the point-of-care device VerifyNow P2-12 in patients treated with prasugrel or clopidogrel coadministered with aspirin, Am Heart J, 157, pp. 562e1-562e9, (2009)
[5] Jeong Y.H., Bliden K.P., Antonino M.J., Et al., Usefulness of the VerifyNow P2-12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies, Am Heart J, 164, pp. 35-42, (2012)
[6] Fabio M., Giuseppe P., Emanuele B., Et al., A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention, JACC Cardiovasc Interv, 5, pp. 281-289, (2012)
[7] Sibbing D., Schulz S., Braun S., Et al., Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement, J Thromb Haemost, 8, pp. 250-256, (2010)
[8] Patti G., Pasceri V., Vizzi V., Et al., Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the antiplatelet therapy for reduction of myocardial damage during angioplasty-bleeding study, Am J Cardiol, 107, pp. 995-1000, (2011)
[9] Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Et al., Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives, J Am Coll Cardiol, 49, pp. 1505-1516, (2007)
[10] Goh C., Churilov L., Mitchell P., Et al., Clopidogrel hyper-response and bleeding risk in neurointerventional procedures, AJNR Am J Neuroradiol, 34, pp. 721-726, (2013)

← 1 2 3 →